by Salynn Boyles Contributing Writer, MedPage Today The FDA has approved AstraZeneca's biologic drug benralizumab (Fasenra) for the add-on maintenance treatment of patients age 12 years and over with severe asthma with an eosinophilic phenotype, the drugmaker announced. Approval was based on pivotal trials showing up to a 51% reduction in the annual asthma exacerbation [... read more]
Multiple randomized trials have suggested that vitamin D supplementation might improve asthma control and reduce severity of asthma attacks. A new meta-analysis bolsters that hypothesis, and may encourage more physicians and people with asthma to consider vitamin D supplements for low vitamin D levels. In a study in Lancet Respiratory Medicine, authors analyzed the experience [... read more]
The post Vitamin D improved asthma symptoms and reduced exacerbations appeared first on PulmCCM.
"Don’t get admitted to the hospital on a weekend." Listen, and you might hear that rueful advice muttered under the breath of a frustrated physician unable to get a prompt Saturday consultation or procedure, the requested specialist being at another hospital, or maybe her son’s soccer game. The weekend effect -- patients admitted on a [... read more]
The post Weekend hospital admissions associated with increased risk of death appeared first on PulmCCM.